Cargando…
Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women, potentially due to ineffectiveness of screening tests for early detection. Patients typically present with advanced disease at diagnosis, whereas, up to 80% relapse and the estimated median progression-free s...
Autores principales: | Boussios, Stergios, Moschetta, Michele, Karihtala, Peeter, Samartzis, Eleftherios P., Sheriff, Matin, Pappas-Gogos, George, Ozturk, Mehmet Akif, Uccello, Mario, Karathanasi, Afroditi, Tringos, Michail, Rassy, Elie, Pavlidis, Nicholas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812175/ https://www.ncbi.nlm.nih.gov/pubmed/33490218 http://dx.doi.org/10.21037/atm.2020.03.156 |
Ejemplares similares
-
Wise Management of Ovarian Cancer: On the Cutting Edge
por: Boussios, Stergios, et al.
Publicado: (2020) -
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
por: Boussios, Stergios, et al.
Publicado: (2019) -
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020) -
Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?
por: Moschetta, Michele, et al.
Publicado: (2020) -
Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches
por: Uccello, Mario, et al.
Publicado: (2020)